AIDX — 20/20 Biolabs, Inc.

Nasdaq · Unknown · Unknown · CIK 1139685 ·
Last close
$0.96
Market Cap
$10.19M
52W High
$2.70
52W Low
$0.78
ADV30
1,217,217
Next earnings
20/20 Biolabs, Inc. develops and commercializes AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. It provides OneTest for Cancer, a multi-cancer early detection, or MCED and OneTest for Longevity, which measures inflammatory biomarkers. It also operates the Clinical Lab Innovation Axcelerator (CLIAx), a CLIA laboratory for overseas diagnostics start-ups. The company was formerly known as 20/20 GeneSystems, Inc. and changed its name to 20/20 Biolabs, Inc. in March 2025. The company was incorporated in 2000 and is based in Gaithersburg, Maryland.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 353,375 62,884 -1,443,356 -2,174,836 5,803,347 4,219,099 3,046,222
Dec 2025 538,274 130,417 -912,846 -1,307,771 4,137,357 1,025,987 4,156,582
Sep 2025 3,239,449 1,144,855 3,130,993
Mar 2025 553,820 165,795 -772,180 -764,577

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-2,825,371
Investing CF
$-5,354
Financing CF
$5,252,589
CapEx
$-5,354
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.35
As of
2026-06-07

Balance + Analyst (yfinance extras)

Retained Earnings
$-35,422,055
Inventory
$104,523
Receivables
$201,481
ST Investments
EBIT TTM
$-5,103,499
Pretax Income TTM
$-5,496,232
Interest Exp TTM
$392,733
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$1,844,688
EBITDA
$-3,921,809
Free Cash Flow
$-1,301,893
Enterprise Value
$7,125,814
Total Cash
$4,219,099
Total Debt
$925,487
Shares Out
10,611,528
Trailing EPS
$-0.49
Book Value
$0.24
ROE
-241.6%
ROA
-58.9%
Div Yield

Annual Trend (SEC EDGAR, last 3y)

Revenues vs Net Income (last 3y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 2,045,133 -3,330,871 -3,738,821 4,137,357 4,156,582 -1,919,720
Dec 2024 1,752,343 -5,661,057 -5,551,667 3,584,408 2,078,926 -2,598,785
Dec 2023 1,424,304 -6,361,462 -6,391,309 6,367,828 2,080,336 -4,479,971

Peers — same industry

TickerNameMarket CapLastDaily %
GARWF Golden Arrow Resources Corp $10.16M $0.06
AGLY Atlantis Glory Inc. $10.27M $0.02
GNVR Genvor Inc $10.01M $0.51
FTRK Fast Track Group $9.92M $0.46
GPMTF GPM Metals Inc. $9.88M $0.06

News headlines (Yahoo Finance, 1h cache)

20/20 Biolabs' Multi-Cancer Early Detection Blood Test Selected by State of Vermont to Screen up to 4,500 Firefighters
2026-05-27 12:31 · Yahoo
20/20 Biolabs Commences Emergency Planning for Ebola & Hantavirus Lab Testing if Outbreak Creates Overflow Demand
2026-05-22 12:31 · Yahoo
20/20 BioLabs Reports First Quarter 2026 Financial Results and Recent Operational Progress
2026-05-20 20:05 · Yahoo
Sidoti Events, LLC's May Micro-Cap Virtual Conference
2026-05-20 11:30 · Yahoo
20/20 BioLabs to Attend Sidoti Micro-Cap Virtual Conference on May 20, 2026
2026-05-14 12:31 · Yahoo
20/20 BioLabs Exclusively Licenses PSA Velocity Algorithm from the University of South Carolina
2026-05-12 12:31 · Yahoo
HEALWELL to Participate in Upcoming 2026 Bloom Burton & Co. Healthcare Investor Conference
2026-04-13 11:00 · Yahoo
BIO-key International, 20/20 Biolabs, Society Pass, and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-04-10 14:00 · Yahoo
20/20 BioLabs Selected by Evexia Diagnostics to Offer OneTest™ for Cancer Through Evexia Platform
2026-04-07 12:31 · Yahoo
20/20 BioLabs Reports Full Year 2025 Financial Results and Recent Operational Progress
2026-03-31 20:57 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.